Skip to main content

7 Result(s)

within Rongxi Wang Remove this filter Nuclear Medicine Remove this filter

and

  1. No Access

    Article

    Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer

    Claudin18.2 (CLDN18.2) is a novel target for diagnosis and therapy of gastrointestinal cancer. This study aimed to evaluate the safety and feasibility of a novel CLDN18.2-targeted nanobody, PMD22, labeled with...

    Rongxi Wang, Zhidong Bai, Wentao Zhong… in European Journal of Nuclear Medicine and M… (2024)

  2. No Access

    Article

    Synthesis, preclinical, and initial clinical evaluation of integrin αVβ3 and gastrin-releasing peptide receptor (GRPR) dual-targeting radiotracer [68Ga]Ga-RGD-RM26-03

    Integrin receptor αvβ3 and gastrin-releasing peptide receptor (GRPR) expression of tumors could be detected using PET imaging with radiolabeled Arg-Gly-Asp (RGD) and the antagonistic bombesin analog RM26, respect...

    Xuejun Wen, Rongxi Wang, Pengfei Xu… in European Journal of Nuclear Medicine and M… (2024)

  3. No Access

    Article

    Comparison of novel PSMA-targeting [177Lu]Lu-P17-087 with its albumin binding derivative [177Lu]Lu-P17-088 in metastatic castration-resistant prostate cancer patients: a first-in-human study

    Prostate-specific membrane antigen (PSMA) is a promising target for diagnosis and radioligand therapy (RLT) of prostate cancer. Two novel PSMA-targeting radionuclide therapy agents, [177Lu]Lu-P17-087, and its alb...

    Linlin Li, Jiarou Wang, Guochang Wang… in European Journal of Nuclear Medicine and M… (2024)

  4. Article

    A prospective head-to-head comparison of [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11 PET/CT in patients with primary prostate cancer

    We aimed to compare the diagnostic performance and biodistribution of two similar PET agents, [68Ga]Ga-P16-093 and [68Ga]Ga-PSMA-11, in the same group of primary prostate cancer (PCa) patients.

    Guochang Wang, Linlin Li, Ming Zhu, Jie Zang… in European Journal of Nuclear Medicine and M… (2023)

    Download PDF (7789 KB) View Article

  5. No Access

    Article

    A prospective head-to-head comparison of 68 Ga-NOTA-3P-TATE-RGD and 68 Ga-DOTATATE in patients with gastroenteropancreatic neuroendocrine tumours

    The aim of this study was to compare 68 Ga-NOTA-3P-TATE-RGD, a dual somatostatin receptor 2– and integrin αVβ3–targeting tracer, to 68 Ga-DOTATATE in a single group of patients with gastroenteropancreatic (GEP)-n...

    Yuanyuan Jiang, Qingxing Liu, Guochang Wang… in European Journal of Nuclear Medicine and M… (2022)

  6. Article

    Correction to: 68Ga-FAPI outperforms 18F-FDG PET/CT in identifying solitary fibrous tumor

    A Correction to this paper has been published: https://doi.org/10.1007/s00259-021-05228-z

    Rongxi Wang, Qingxing Liu, Huimin Sui… in European Journal of Nuclear Medicine and M… (2021)

    Download PDF (404 KB) View Article

  7. No Access

    Article

    68Ga-FAPI outperforms 18F-FDG PET/CT in identifying solitary fibrous tumor

    Rongxi Wang, Qingxing Liu, Huimin Sui… in European Journal of Nuclear Medicine and M… (2021)